Skip to search formSkip to main contentSkip to account menu

Embola ionis

Known as: Heliodines ionis 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Design of the First-in-Human Study of IONIS-MAPTRx, a Tau-lowering Antisense Oligonucleotide, in Patients With Alzheimer Disease (S2.006)
Objective: To design a study to test IONIS-MAPT Rx an antisense oligonucleotide (ASO) developed to specifically, potently and… 
2017
2017
Electromechanical delays during a fatiguing exercise and recovery in patients with myotonic dystrophy type 1
PurposeThe partitioning of the electromechanical delay by an electromyographic (EMG), mechanomyographic (MMG) and force combined… 
Review
2017
Review
2017
Apolipoprotein(a) Antisense Oligonucleotides: A New Treatment Option for Lowering Elevated Lipoprotein(a)?
BACKGROUND Lipoprotein(a) [Lp(a)] is a particle similar to LDL that contains an additional protein called apolipoprotein(a) [apo… 
2017
2017
Pharmacokinetics and Pharmacodynamics of Ionis-FXIRx, an Antisense Inhibitor of Factor XI, in Patients with End-Stage Renal Disease on Hemodialysis
BACKGROUND: Patients with end-stage renal disease (ESRD) on hemodialysis are at high risk of both thrombotic and bleeding events… 
Review
2017
Review
2017
Antisense Oligonucleotides for the Treatment of Hypertriglyceridemia and Hyperlipoproteinemia(a)
Elevated triglycerides are associated with an increased risk of both pancreatitis and cardiovascular disease (CVD). Increased… 
2017
2017
Podsystem lokalizacyjny w platformie IONIS
2017
2017
UWB positioning system for elderly persons tracking in IONIS AAL platform
UWB (Ultra Wideband) indoor positioning system infrastructure is typically composed of anchor nodes deployed in the area covered… 
2017
2017
Market watch: Upcoming market catalysts in Q3 2017
Market catalysts in the third quarter of 2017 include top-line phase III trial results for several therapeutics: patisiran… 
2016
2016
A phase I dose escalation, safety and pharmacokinetic (PK) study of AZD5312 (IONIS-ARRx), a first-in-class Generation 2.5 antisense oligonucleotide targeting the androgen receptor (AR)
1997
1997
The systematic position of Heliodines loriculata Meyrick (Yponomeutoidea: Heliodinidae)
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)